Press coverage about Johnson & Johnson (NYSE:JNJ) has been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than 6,000 blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 1.96 on their scale. InfoTrie also gave media coverage about the company an news buzz score of 8 out of 10, meaning that recent press coverage is very likely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have impacted Johnson & Johnson’s ranking:
- Global Pharmerging Market Competition By Players With Rising Growth: Pfizer, Sanofi, GlaxoSmithKline, AstraZeneca, Novartis and Johnson & Johnson (openpr.com)
- Edwards Lifesciences Stock: Analysts Remain Bullish (finance.yahoo.com)
- Top Analyst Reports for Johnson & Johnson, Thermo Fisher & Goldman Sachs (zacks.com)
- Campbell Soup aims at former Pinnacle Foods chief to take CEO job (finance.yahoo.com)
- Time magazine names Tampa Bay-based invention among the best in 2018 (finance.yahoo.com)
Shares of Johnson & Johnson stock opened at $145.85 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The stock has a market cap of $392.88 billion, a PE ratio of 19.98, a PEG ratio of 2.29 and a beta of 0.58. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.75.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.90 EPS. Research analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.47%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research report on Wednesday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research report on Friday, September 14th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Finally, Citigroup upped their price target on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $143.47.
In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total value of $1,225,211.15. Following the transaction, the chief accounting officer now owns 17,284 shares in the company, valued at $2,508,772.60. The disclosure for this sale can be found here. Insiders have sold a total of 351,748 shares of company stock worth $51,092,647 over the last quarter. Corporate insiders own 0.22% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Market Capitalization
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.